Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bjoern Jacobsen

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Regulatory Toxicology and Pharmacology : RTP|May 21, 2025
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeuticsAnna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
Annals of Clinical and Translational Neurology|November 24, 2020
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophyRobert C Sergott, Giulia M Amorelli, Giovanni Baranello, et al.
Toxicologic Pathology|February 11, 2025
Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and DevelopmentKerstin Hahn, Bettina Amberg, Josep M Monné Rodriguez, et al.
Journal of Medicinal Chemistry|July 26, 2018
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)Hasane Ratni, Martin Ebeling, John Baird, et al.
Nature Cancer|March 1, 2021
CD25-T<sub>reg</sub>-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunityIsabelle Solomon, Maria Amann, Anne Goubier, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Regulatory Toxicology and Pharmacology : RTP|May 21, 2025
Considerations for use of humanized IgG1/4 Göttingen minipigs in safety assessment of antibody-based therapeuticsAnna Engstrom, Tine Dahlbaek Hannibal, Jerome Egli, et al.
Annals of Clinical and Translational Neurology|November 24, 2020
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophyRobert C Sergott, Giulia M Amorelli, Giovanni Baranello, et al.
Toxicologic Pathology|February 11, 2025
Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and DevelopmentKerstin Hahn, Bettina Amberg, Josep M Monné Rodriguez, et al.
Journal of Medicinal Chemistry|July 26, 2018
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)Hasane Ratni, Martin Ebeling, John Baird, et al.
Nature Cancer|March 1, 2021
CD25-T<sub>reg</sub>-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunityIsabelle Solomon, Maria Amann, Anne Goubier, et al.
Pageof 2